| |
original article |
Date |
Title |
Authors All Authors |
| 1 |
[GO] |
2024―Dec―13 |
Ingavirin might be a promising agent to combat Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) |
Ivan Malík, Gustáv Kováč, Tereza Padrtová, Lucia Hudecová |
| 2 |
[GO] |
2024―Apr―26 |
Hyperferritinemia as a factor associated with poor prognosis in COVID-19 patients |
Nuhad Mohammed Al-Dulaimi, Mahmood Jassim Mohammed, Saad T. Mutlk, Khalid F Al-Rawi, Hameed Hussein Ali, Bilal J. M., et al. (+4) Faisal Al-Ani, Osamah Al-Ani, Yaqout A. Hamed, Aus T. Ali |
| 3 |
[GO] |
2023―Jun―06 |
Are some COVID-19 vaccines better than others regarding the short-term side effects? |
Radhwan Al-Zidan, Omeed Darweesh, Muhanad Salah, Pshtiwan Bebane, Hemn Ahmed, Ghayth Abdulrazzaq, et al. (+2) Sadeel Shanshal, Nohad Alomari |
| 4 |
[GO] |
2023―Feb―21 |
The efficacy of triazavirin (riamilovir)-based treatment for coronavirus disease 2019 (COVID-19) in clinical trials and preliminary practical experiences |
Ivan Malík, Gustáv Kováč, Lucia Hudecova |
| 5 |
[GO] |
2022―Apr―25 |
Etické a zákonné požadavky na podstoupení očkování k prevenci nemoci COVID-19 |
Aleš Franc, Vladimír Bíba |
| 6 |
[GO] |
2021―Aug―13 |
Triazavirin might be the new hope to fight Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) |
Malík Ivan, Čižmárik Jozef, Kováč Gustáv, Pecháčová Mária, Hudecová Lucia |
|
